What Pfizer Knew — and When: The 35-Year Paper Trail Behind the Depo-Provera Lawsuit

Women in Canada received warnings about Depo-Provera's potential brain tumor risks before American women did. Studies suggesting a link between the drug's active ingredient and meningioma growth date back to 1989. Pfizer turned over more than 8,000 previously privileged documents in discovery. And the FDA did not add a meningioma warning to the U.S. label until December 2025 — 33 years after the drug was approved for contraception.

This is not a story about science that was unknown. It is a story about what was known, who knew it, and what they chose to do — or not do — with that information. It is the central question in MDL 3140, the federal multi-district litigation before Judge M. Casey Rodgers in the Northern District of Florida, where 3,769 cases are pending as of May 2026.

1. The 1989 Research: A Warning Signal Pfizer Allegedly Ignored

The scientific connection between progestogens and meningioma growth is not a recent discovery. Research suggesting that progesterone receptor expression plays a role in meningioma development was available in the medical literature as early as 1989 — the year that Pfizer's predecessor company, Upjohn, was still pushing for FDA approval of Depo-Provera for contraceptive use in the United States.

Plaintiffs in MDL 3140 allege that Pfizer and Upjohn "failed to investigate the possible link between meningiomas and the hormones used in Depo-Provera, citing studies conducted as far back as 1989." The core legal argument is not simply that the company missed emerging science — it is that the company had sufficient scientific signals to trigger an investigation and a duty to warn, and did neither.

The timeline is crucial to the legal analysis. Under the failure-to-warn doctrine, liability attaches when a manufacturer knew or reasonably should have known of a risk — not only when that risk achieves scientific certainty. Plaintiffs argue that the progression of research from 1989 through the landmark 2024 BMJ study (5.55x risk increase for 1+ year users) represents a 35-year arc of evidence that the company had access to and chose not to act on.

2. The Canada Warning Gap: What U.S. Women Weren't Told

One of the most damaging facts for Pfizer in MDL 3140 is simple and intuitive: Canadian women received warnings about Depo-Provera's potential meningioma risk before American women did.

Canadian and European drug labeling regulations require manufacturers to reflect emerging safety signals in labeling more proactively than the U.S. system, which generally requires FDA approval for label changes. Pfizer updated its Canadian Depo-Provera labeling to include meningioma risk information before any equivalent update appeared on the American product label.

Plaintiffs argue that the Canada warning gap is particularly powerful against Pfizer's preemption defense. If Pfizer could add a meningioma warning in Canada, it had the scientific basis to pursue one in the U.S. as well — making any claim that it was scientifically impossible to warn American women much harder to sustain.

3. The 8,000+ Documents: What Discovery Is Uncovering

In the discovery phase of MDL 3140, Pfizer produced more than 8,000 documents that had previously been withheld under claims of privilege — documents that plaintiffs' attorneys are now examining for evidence of what the company knew internally about the meningioma risk.

In major pharmaceutical litigation, privileged document production frequently yields the most important evidence. These documents may include:

The analysis of these 8,000+ documents is ongoing. In landmark pharmaceutical cases like Vioxx and Roundup, internal document production ultimately became the most compelling evidence of corporate awareness and reckless disregard — generating the punitive damage exposure that drives billion-dollar settlements.

4. Pfizer's FDA Label Change Requests — and the Rejections

Pfizer's defense in MDL 3140 centers on a specific narrative: it tried to add a meningioma warning but the FDA rejected the request. The company claims the FDA rejected a formal supplemental label application in February 2024 — and that this was actually the second time the FDA had refused such a request.

However, plaintiffs' attorneys have aggressively challenged this narrative on several grounds:

• No documentation produced. Pfizer "did not provide any supporting documentary evidence, such as the company's requested label change, what scientific support was provided, the FDA's supposed denial letter, or any communications between Pfizer and the FDA on the issue." Plaintiffs argue that if the FDA truly rejected the request twice, Pfizer should be able to prove it.
• What was in the application matters. If Pfizer submitted an incomplete or inadequately supported application, a rejection does not necessarily mean the FDA concluded the risk was non-existent. It may simply mean the submission was insufficient — a very different legal implication.
• The Canada evidence undermines the FDA excuse. If the science was adequate to warn Canadians, why was it inadequate to submit to the FDA?
• The December 2025 approval contradicts the "FDA blocked us" story. The FDA ultimately approved a meningioma warning in December 2025. Pfizer argues it requested this latest change itself. Plaintiffs argue this demonstrates the warning was achievable years earlier.

5. December 2025: The Warning That Finally Arrived

On December 17, 2025, the FDA approved new warning language for Depo-Provera CI and Depo-SubQ Provera 104, formally acknowledging for the first time on the U.S. label that meningioma cases had been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use.

The approved language instructs physicians to monitor patients for meningioma signs and symptoms and to discontinue the drug if a meningioma is diagnosed. This represents the first federal regulatory acknowledgment of the risk — one that plaintiffs argue could and should have appeared on U.S. labels years earlier.

6. What "Failure to Warn" Means Legally

The legal framework underlying most Depo-Provera lawsuits is the failure-to-warn doctrine in pharmaceutical products liability law. Understanding this doctrine is essential for families evaluating their legal options.

In pharmaceutical law, the "learned intermediary" doctrine generally holds that a drug manufacturer's duty to warn runs to the prescribing physician, not directly to the patient. The physician then serves as a learned intermediary between the manufacturer and the patient. However, a failure-to-warn claim succeeds when:

1. The manufacturer knew or should have known of the risk. Plaintiffs must show that the science was sufficiently advanced that a reasonable pharmaceutical company exercising due diligence would have identified the meningioma risk and pursued a label update.
2. The warning provided was inadequate. The pre-December 2025 U.S. label contained no meningioma warning at all. This is the easiest element for plaintiffs to establish — the absence of any warning is, by definition, an inadequate warning.
3. The inadequate warning caused the plaintiff's injury. Plaintiffs must connect the failure to warn to their specific harm — arguing that if their physician had been warned, the physician would have either not prescribed Depo-Provera, prescribed it for a shorter duration, or monitored for meningioma development and caught it earlier.

The strength of the "what Pfizer knew" evidence directly determines how much of a damages case plaintiffs can build. If the 8,000+ documents show that internal risk assessments identifying the meningioma signal were buried or ignored, punitive damages — which can multiply compensatory damages by 3x to 10x — become available.

7. Pfizer's Defense: "The FDA Blocked Us"

Pfizer's primary affirmative defense is federal preemption — the legal argument that federal drug labeling law (administered by the FDA) preempts state tort law failure-to-warn claims. The logic: if the FDA sets what must be on the label, a drug company cannot be sued under state law for failing to put something on the label that the FDA did not approve.

Pfizer argues that it submitted a formal request to add a meningioma warning — and the FDA rejected it in February 2024. Under the Supreme Court's decision in Wyeth v. Levine (2009), a manufacturer can unilaterally update a warning under the "Changes Being Effected" (CBE) regulation — but only if there is "newly acquired information" that reasonably supports the change. Pfizer argues the FDA's rejection effectively determined that such information did not exist.

The December 2025 FDA approval of the warning, however, severely damaged this defense. As one legal analyst put it, Pfizer's "clean preemption narrative" had a hole blown straight through it. Judge Rodgers immediately ordered supplemental briefing to address the December 2025 development, and the preemption question remains one of the most contested issues heading into the June 2026 Daubert hearings.

8. What This Paper Trail Means for Individual Cases

For women who used Depo-Provera and have been diagnosed with a meningioma, the "what Pfizer knew" question has direct implications for case value:

Frequently Asked Questions